WallStSmart

CapsoVision, Inc. Common Stock (CV)vsEdwards Lifesciences Corp (EW)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 47847% more annual revenue ($6.67B vs $13.92M). EW leads profitability with a 15.3% profit margin vs -210.1%. EW earns a higher WallStSmart Score of 54/100 (C-).

CV

Avoid

14

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -13.46

EW

Buy

54

out of 100

Grade: C-

Growth: 5.3Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CV.

EWUndervalued (+69.2%)

Margin of Safety

+69.2%

Fair Value

$257.48

Current Price

$107.15

$150.33 discount

UndervaluedFair: $257.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CV1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

EW4 strengths · Avg: 9.8/10
Operating MarginProfitability
30.1%10/10

Strong operational efficiency at 30.1%

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Market CapQuality
$59.81B9/10

Large-cap with strong market position

Areas to Watch

CV4 concerns · Avg: 3.8/10
Price/BookValuation
12.3x4/10

Trading at 12.3x book value

Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$323.27M3/10

Smaller company, higher risk/reward

EW3 concerns · Avg: 3.0/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
60.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : CV

The strongest argument for CV centers on Debt/Equity.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 30.1%. Revenue growth of 10.5% demonstrates continued momentum.

Bear Case : CV

The primary concerns for CV are Price/Book, Revenue Growth, EPS Growth.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 60.5x leaves little room for execution misses.

Key Dynamics to Monitor

CV profiles as a turnaround stock while EW is a mature play — different risk/reward profiles.

EW is growing revenue faster at 10.5% — sustainability is the question.

EW generates stronger free cash flow (507M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EW scores higher overall (54/100 vs 14/100), backed by strong 15.3% margins and 10.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CapsoVision, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company is headquartered in Saratoga, California.

Visit Website →

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?